"R&D Trends: Autism Spectrum Disorders - Pipeline growth reflects increasing interest in autism" Published
The autism spectrum disorders (ASDs) market is a challenging one to penetrate; since 2006 only two products have been successful in entering this marketplace: Risperdal (risperidone; Johnson & Johnson) and Abilify (aripiprazole; Bristol-Myers Squibb). However, as additional agents near the market, increasing interest in ASDs has led to a sizable growth in the clinical pipeline.
View full press release